3590.75 135.05 (3.91%)

27.75% Fall from 52W High

241.6K NSE+BSE Volume High volume today

BSEApr 19, 2021 04:00 PM



Get corporate announcements alerts
3590.75
3.91%
AstraZeneca Pharma India Ltd - 506820 - Statement Of Investor Complaints For The Quarter Ended March 2021
BSE India
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- PRATAP RUDRADesignation :- Company Secretary and Compliance Officer
3590.75
3.91%
3590.75
3.91%
3590.75
3.91%
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And ...
BSE India
This is to certify that, Integrated Registry Management Services Private Limited are the Company's Registrar and Transfer Agents and that all activities in relation to the share transfer are maintained by Integrated Registry Management Services Private Limited. We are also attaching the certificate received from our Registrar and Transfer Agents, Integrated Registry Management Services Private Limited along with this letter.
3590.75
3.91%
3590.75
3.91%
AstraZeneca Pharma India Ltd.    
17 Mar 2021, 05:39PM
3590.75
3.91%
default
3590.75
3.91%
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Import And Market Permission ...
BSE India
This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg film coated tablets (TagrissoTM). Osimertinib 40mg/80mg film coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses.
3590.75
3.91%
3590.75
3.91%
Total Votes: 87
BUY
SELL
HOLD
70.11%
18.39%
11.49%
  • Stock Price (3541.45) crossed above 50 Day SMA (3462.08) on 13 April, 2021
  • Stock Price (3389.95) crossed above 30 Day SMA (3318.63) on 12 April, 2021
  • Day volume (378308.0) was 620% of the Month Average Volume (60931.0) on 01 April, 2021
  • Stock Price (3748.55) crossed below 200 Day SMA (3832.33) on 09 February, 2021
  • Month Change by -20.13% (Crossed threshold 20%) on 29 January, 2021
More triggered alerts
Ex-Date Dividend Amount Dividend Type Record Date
Aug. 20, 20202.00INTERIMAug. 21, 2020
Aug. 20, 20191.00INTERIMAug. 21, 2019
July 9, 20123.50FINAL-
July 7, 201110.00FINAL-
May 6, 201010.00FINAL-
All dividends by ASTRAZEN
Ex-Date Dividend Old FVNew FV Record Date
June 15, 2006102June 22, 2006
All splits by ASTRAZEN